Cargando…
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
In this multicenter, open-label, randomized controlled trial, we determined whether 2-month prednisolone therapy for steroid-sensitive nephrotic syndrome was inferior or not to 6-month therapy despite significantly less steroid exposure. The primary end point was time from start of initial treatment...
Autores principales: | Yoshikawa, Norishige, Nakanishi, Koichi, Sako, Mayumi, Oba, Mari S, Mori, Rintaro, Ota, Erika, Ishikura, Kenji, Hataya, Hiroshi, Honda, Masataka, Ito, Shuichi, Shima, Yuko, Kaito, Hiroshi, Nozu, Kandai, Nakamura, Hidefumi, Igarashi, Takashi, Ohashi, Yasuo, Iijima, Kazumoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284810/ https://www.ncbi.nlm.nih.gov/pubmed/25054775 http://dx.doi.org/10.1038/ki.2014.260 |
Ejemplares similares
-
Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)
por: Hama, Taketsugu, et al.
Publicado: (2018) -
Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014) -
Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)
por: Horinouchi, Tomoko, et al.
Publicado: (2018) -
Rituximab for nephrotic syndrome in children
por: Iijima, Kazumoto, et al.
Publicado: (2016) -
Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
por: Iijima, Kazumoto, et al.
Publicado: (2017)